Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Blood (2019) 134 (Supplement_1): 3091.

https://doi.org/10.1182/blood-2019-130247

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment

Keertik Fulzele, PhD, Cristina Panaroni, PhD, Rosemary Soucy, Ka Tat Siu, PhD, Kenta Mukaihara, MD PhD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 4476.

https://doi.org/10.1182/blood-2018-99-118377

Published: 2018

Journal Articles

The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma

Kenta Mukaihara, MD PhD, Ka Tat Siu, PhD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Rosemary Soucy, Cherrie Huang, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2018-99-114922

Published: 2018

Journal Articles

Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Cristina Panaroni, PhD, Keertik Fulzele, PhD, Rosemary Soucy, Ka Tat Siu, PhD, Kenta Mukaihara, MD PhD, Cherrie Huang, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2018-99-118482

Published: 2018

Journal Articles

Overcoming MCL1 Resistance in Multiple Myeloma

Ka Tat Siu, PhD, Cherrie Huang, Cristina Panaroni, PhD, Kenta Mukaihara, MD PhD, Keertik Fulzele, PhD, Rosemary Soucy, Justin Cidado, PhD, Lisa Drew, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 472.

https://doi.org/10.1182/blood-2018-99-116377

Published: 2018

Journal Articles

Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM)

Kristen M Rosenthal, PhD, Irene M. Ghobrial, MD, Carol Ann Huff, MD, Sagar Lonial, MD, Noopur Raje, MD, Kevin L Obholz, PhD, Shaji K. Kumar, MD

Blood (2018) 132 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2018-99-118941

Published: 2018

Journal Articles

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Nina Shah, MD, Melissa Alsina, MD, David S Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L Kaufman, MD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Kristen Hege, MD, Fabio Petrocca, MD, Jesus G. Berdeja, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 488.

https://doi.org/10.1182/blood-2018-99-116953

Published: 2018

Journal Articles

Analysis of Hospitalization and Readmissions after CAR T Cell Therapy

Elizabeth O'Donnell, MD, Hao Deng, MD, Kyan Safavi, William Driscoll, MD, Milcho Nikolov, Andrew J Yee, MD, Noopur Raje, MD, Matthiew Frigault, MD MSc, Dusan Handiziar, MD

Blood (2018) 132 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2018-99-112254

Published: 2018

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Patient Preferences for Multiple Myeloma (MM) Treatment: Interim Analysis of a Discrete Choice Experiment

Caroline McKay, PhD, Eric M Maiese, PhD, Joseph Chiarappa, PhD, M. Janelle Cambron-Mellott, PhD, Martine Maculaitis, PhD, Nicole Alunni, MS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3586.

https://doi.org/10.1182/blood-2018-99-112921

Published: 2018

Journal Articles

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

Alexander M. Lesokhin, MD, Noopur Raje, MD, Cristina J Gasparetto, MD, Justine Walker, MD, Heike I. Krupka, PhD PMP, Tenshang Joh, PhD, Carrie T. Taylor, PhD MHS, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2018-99-110427

Published: 2018

Journal Articles

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Yi Lin, MD PhD, Noopur Raje, MD, Nikhil Munshi, MD, David Siegel, MD PhD, Michaela Liedtke, MD, Sundar Jagannath, MD, Marcela V. Maus, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Kristen Hege, MD, Richard A. Morgan, PhD, Michael Travis Quigley, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 740.

https://doi.org/10.1182/blood.V130.Suppl_1.740.740

Published: 2017

Journal Articles

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 2767.

https://doi.org/10.1182/blood.V130.Suppl_1.2767.2767

Published: 2017

Journal Articles

Final Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) in Transplant-Ineligible Multiple Myeloma

Elizabeth O'Donnell, MD, Jacob Laubach, MD, Andrew J Yee, MD, Tianqi Chen, Carol Ann Huff, MD, Frank G. Basile, MD, Philip Wade, MD, Claudia Paba-Prada, MD, Irene M. Ghobrial, MD, Robert Schlossman, MD, Jill Burke, Harrington Cynthia, Kathleen Lively, Hannah Lyons, Nikhil Munshi, MD, Lorenzo Trippa, PhD, Kenneth C Anderson, MD, Paul G Richardson, MD, Noopur Raje, MD

Blood (2017) 130 (Supplement 1): 3126.

https://doi.org/10.1182/blood.V130.Suppl_1.3126.3126

Published: 2017

Journal Articles

Role of Sclerostin in Multiple Myeloma Progression

Cristina Panaroni, PhD, Keertik Fulzele, PhD, Ka Tat Siu, PhD, Peter Wang, BS, Noopur Raje, MD

Blood (2017) 130 (Supplement 1): 4341.

https://doi.org/10.1182/blood.V130.Suppl_1.4341.4341

Published: 2017

Journal Articles

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Joseph Mikhael, MD, Saad Z Usmani, MD, Noopur Raje, MD, William Bensinger, MD, Dheepak Kanagavel, MD PhD, Lei Gao, Samira Ziti-Ljajic, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1887.

https://doi.org/10.1182/blood.V130.Suppl_1.1887.1887

Published: 2017

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Expression of B Cell Maturation Antigen (BCMA) and Transmembrane Activator and Caml Interactor (TACI) Are Correlated and Can be Targeted at Multiple Points during the Course of Multiple Myeloma

Allison O. Taylor, Matthew J. Frigault, MD, Felipe Bedoya, PhD, Michelle E. DeLelys, Alexandra J. Shay, Rachel T. Nicholson, Noopur Raje, MD, Fredric I. Preffer, PhD, Timothy A. Graubert, MD, Marcela V. Maus, MD PhD

Blood (2017) 130 (Supplement 1): 5363.

https://doi.org/10.1182/blood.V130.Suppl_1.5363.5363

Published: 2017

NARROW

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment

The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma

Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Overcoming MCL1 Resistance in Multiple Myeloma

Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM)

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Analysis of Hospitalization and Readmissions after CAR T Cell Therapy

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Patient Preferences for Multiple Myeloma (MM) Treatment: Interim Analysis of a Discrete Choice Experiment

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Final Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) in Transplant-Ineligible Multiple Myeloma

Role of Sclerostin in Multiple Myeloma Progression

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Expression of B Cell Maturation Antigen (BCMA) and Transmembrane Activator and Caml Interactor (TACI) Are Correlated and Can be Targeted at Multiple Points during the Course of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only